A role of NLRP3 inflammasome-driven inflammation in cancer development was partly supported by the finding that the anti-IL-1β therapy using canakinumab in the CANTOS trial is correlated with a reduction in the incidence of lung cancer in the patient population studied (Ridker et al., 2017b). Here, NLRP3 is linked to lung carcinoma.